AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 15 Sep - Innova Captab will attend Anand Rathi G-200 Summit 2026 on 21 September 2026 in Mumbai.
Source: Bse
Innova Captab Limited (INNOVACAP)
Small CapPharma stocks · Small cap · NSE
Innova Captab Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 04:45 am ISTDetails
Quote21 Oct, 04:45 am IST
Base fundamentals06 Oct 2026 · screener
Latest result22 Aug, 03:26 am IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags03 May 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
76BullishSMA20 +3.6% / mo · RSI oversold · MACD − · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 61
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
INNOVACAPD candles · FIT view+38.9%Latest close ₹1001.70 on 2026-10-19
Bar
-1.8%
RSI
30
MACD hist
-24.23
52W pos
52%
2026-10-19O ₹1019.80H ₹1028.10L ₹992.00C ₹1001.70Vol 39,267 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
INNOVACAPNifty PharmaNifty 500
- INNOVACAP
- +2.9%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- +8.5 pp
Chart stats
19 Oct 2026- From 52W high
- -26.0%
- 52W range position
- 52%
- ATR (14)
- 5.0%
- Volume vs 20D
- 0.31x
- Avg traded value
- ₹15.1 Cr
- 20D price channel
- ₹992 - ₹1,353.5
₹1,353.5
₹622 - ₹1,353.5
₹50.3
Latest completed session
20-session average
45.5% annualized volatility
Research snapshot
What the evidence says now
Mixed fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Momentum only
Trend is strong but fundamentals do not support a clean investment thesis.
U-Score
Legacy · FAIR VALUE48
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Excellent100
Revenue +33.8% · PAT +41.9% YoY
Technical
Bullish76
Price trend and sector-relative-strength timing.
Valuation
Legacy model+17.3%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence81
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Excellent · 100/100Rev +34% YoY · PAT +42% YoY · margin expansion · +5% QoQ · operating leverage
Filed 21 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹471 Cr | +33.8% | +5.1% |
| EBITDA | ₹73 Cr | +40.4% | +12.3% |
| Operating margin | 16.0% | +100 bps | +100 bps |
| PAT | ₹44 Cr | +41.9% | +15.8% |
| PAT margin | 9.3% | +53 bps | +86 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 42.60
- P/B
- 5.99
- EV/EBITDA
- 22.63
- Market Cap
- 6557.00Cr
Profitability
- ROE
- 13.70%
- ROCE
- 15.00%
- ROA
- 8.39%
- Dividend Y
- 0.17%
Growth (CAGR)
- Revenue 5Y
- 32.00%
- EPS 5Y
- 32.00%
- Revenue 3Y
- 21.00%
- EPS 3Y
- 28.00%
Balance Sheet
- Debt/Equity
- 0.32
- Interest Coverage
- 14.39×
- Altman Z
- 7.70
- Book Value
- 191.00
Cash Flow
- FCF Yield
- 0.15%
- FCF Positive Y
- 4/5
- OCF
- 117.00 Cr
- EPS TTM
- 26.91
Shareholding
- Promoter Hold
- 50.90%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 72%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 1,630+31.0% vs prev
Net Profit
₹ CrLatest: 141+10.2% vs prev
Return on Equity
%Latest: 12.9-3.2% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term uptrend intact. RSI 30. Wait for confirmation.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 rising (~3.5% over last month) — short-term momentum positive.
- RSI(14) at 30 — oversold zone; bounce conditions.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 26% off 52W high · 61% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
82
RS percentile
Stage 2 UptrendEstablished S2
1M return
-15.1%
3M return
+2.9%
6M return
+41.0%
1Y return
+23.7%
RS 1D
0
RS 20D
-5
Sector rank
#1
Industry rank
#11
Stage evidence
- Price is 6.3% above the 30-week proxy.
- The 50-DMA is above the 30-week proxy and its slope is rising +7.2%.
- Both 3-month and 6-month returns are positive.
50-DMA
price below
200-DMA
price above
S2 entered
27 May 2026
S2 age
102 trading sessions
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
261 observations
19 Oct 2026Value 124.74-0.76%
RS vs Nifty 500125
Valuation & peers
U-Score 48 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Valuation & peers
U-Score 48 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Financial Turnaround
Fundamental score breakdown
U band · FAIR VALUEValuation4/30
Growth17/25
Quality9/20
Balance Sheet9/15
Cash Flow4/10
Piotroski
8/9 (+5)
Penalties
0
Raw sum
48
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
48/100 · legacy band FAIR VALUE
Positive drivers
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 17.3%.
- Growth contributes 17/25 to the score.
Main drags
- Valuation is weaker at 4/30; verify the latest quarterly trend.
- Cash flow is weaker at 4/10; verify the latest quarterly trend.
- Quality is weaker at 9/20; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
42.6
PB
6.0
EV/EBITDA
22.6
ROE
13.7%
ROCE
15.0%
FCF Yield
0.1%
Debt/Equity
0.3
MoS
+17.3%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
48
Previous: 48
Legacy U-Score band
FAIR VALUE
Previous: FAIR VALUE
Margin of safety
+17.3%
Previous: +17.3%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
46
46
46
48
48
48
48
48
48
48
48
48
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹340.07
-194.6% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹1,210.95
+17.3% MoS
PEG
1.40
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
SANOFI
Small
Sanofi India Limited
Pharmaceuticals
match 167
53
15.8
47.1%
-305%
FAIR VALUE
BLISSGVS
Small
Bliss GVS Pharma Limited
Pharmaceuticals
match 166
39
51.4
11.8%
-8%
WATCHLIST
FDC
Small
FDC Limited
Pharmaceuticals
match 166
40
17.5
11.2%
-180%
WATCHLIST
NOVARTIND
Small
Novartis India Limited
Pharmaceuticals
match 165
40
49.7
11.6%
-8%
WATCHLIST
ZOTA
Small
Zota Health Care LImited
Pharmaceuticals
match 163
26
—
-15.0%
—
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Innova Captab Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
81Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 93rd percentile of the scored universe and 90th percentile within Pharma. No major sub-score weakness stands out.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
47 docs text-extracted · 22 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
93rd percentile
overall median 67 · Pharma: 90th pctile, median 70 · Small: 95th pctile, median 66
Evidence depth
Financial-only
47 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
78
strong · holding, pledge, alignment
Cash flow
77
strong · profit to cash conversion
Balance sheet
89
strong · leverage and solvency
Discipline
68
acceptable · capital discipline
Results
95
strong · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 0.2%.
- ▸4 years of positive FCF.
- ▸4/4 latest quarters had positive YoY revenue growth.
Trust risks
- ▸No major Trust Lite risk flags.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Innova Captab Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Credit rating
Announcement under Regulation 30 (LODR)-Credit Rating 29 Sep - CARE upgraded Innova Captab’s ratings to CARE A+ Stable and CARE A1+ on Rs 459.60 crore facilities.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 5 Sep - Pursuant to the regulation 30 read with schedule III, Part A, Para A and regulation 47 of SEBI (LODR) Regulations, 2015 ("Listing regulations") ....
Source: Bse
Annual report
Reg. 34 (1) Annual Report. 4 Sep
Source: Bse
Investor presentationAug 2026
Aug 2026 · PPT
Source: Bse
Concall transcriptAug 2026
Aug 2026 · Transcript
Source: Bse
AnnouncementAug 2026
Aug 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 23 Aug - The Board of the Company at its meeting commenced on 21st August 2026 at 23:16 hours (IST) and concluded on 22nd August 2026 at 00:25 …
Source: Bse
AnnouncementAug 2026
Aug 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 12 Aug - The Board of the Company at its meeting held on Tuesday, 11th August, 2026, has approved the unaudited (standalone and consolidated) financial results ....
Source: Bse
Annual report
Approval Of AGM Notice 22 Aug - Board approved notice for Innova Captab’s 22nd AGM for FY2026; annual report to follow.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 25 Jun - Pursuant to the regulation 30 read with schedule III, Part A, Para A of SEBI LODR Regulations, 2015, as amended, we are enclosing herewith copies …
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 6 Jun - Pursuant to regulation 30 read with schedule III Part A Para A and Regulation 47 of SEBI (LODR) 2015 as amended time to time and …
Source: Bse
Annual report
Reg. 34 (1) Annual Report. 4 Jun
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.